Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Centre Oscar Lambret
Seagen Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
Case Comprehensive Cancer Center
University of Chicago
Tianjin Medical University Cancer Institute and Hospital
Peter MacCallum Cancer Centre, Australia
University of California, Irvine
Second Affiliated Hospital, School of Medicine, Zhejiang University
Dana-Farber Cancer Institute
University of Maryland, Baltimore
University of California, San Diego
University of Alberta
Washington University School of Medicine
University of Virginia
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University of California, San Diego
Wake Forest University Health Sciences
Daiichi Sankyo
Instituto Oncoclinicas
Aveta Biomics, Inc.
University of Arizona
GlaxoSmithKline
Incyte Corporation
Medical University of South Carolina
Centre Henri Becquerel
West China Hospital
Centre Paul Strauss
University of Chicago
UNICANCER
Rigshospitalet, Denmark
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
I-Mab Biopharma US Limited
University of Colorado, Denver
Gustave Roussy, Cancer Campus, Grand Paris
Sir Mortimer B. Davis - Jewish General Hospital
Gustave Roussy, Cancer Campus, Grand Paris
Pfizer
West China Hospital
University of Zurich
University of Maryland, Baltimore
M.D. Anderson Cancer Center